Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03521648Recruiting

Database for the Assessment of Efficacy and Safety of BPH Treatment

Role: lead

NCT03457805Not ApplicableUnknown

Prostatic Artery Embolization in Advanced Prostate Cancer

Role: lead

NCT04245566Phase 3Unknown

Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH

Role: lead

NCT02917161Not ApplicableCompleted

Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study

Role: lead

All 4 trials loaded